Market Spotlight: Acne
Market Spotlight: Acne
$1,318.00
This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2019, there were approximately 612.5 million prevalent cases of acne worldwide, and forecasts that number to increase to 658.6 million prevalent cases by 2028.
- Approved drugs in the acne space focus on a wide variety of targets. These drugs are administered via the oral and topical routes.
- The majority of industry-sponsored drugs in active clinical development for acne are in Phase II. Therapies in development for acne focus on a wide variety of targets. The majority of the pipeline drugs are administered via the topical route, with the remainder being oral, subcutaneous, intranasal, or intravenous formulations.
- The only high-impact upcoming event in the acne space is topline Phase II trial results for LUT014. The overall likelihood of approval of a Phase I dermatology-general asset is 19.8%, and the average probability a drug advances from Phase III is 67.3%. Drugs, on average, take 8.8 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for acne have been in the late phases of development, with 53% of trials in Phase III–IV, and 47% in Phase I–II.
- The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the acne space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for acne, with 35 trials.
- GlaxoSmithKline leads industry sponsors with by far the highest overall number of clinical trials for acne, followed by AbbVie.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Topical therapy
9 Systemic therapy
10 Physical treatments
11 EPIDEMIOLOGY
14 MARKETED DRUGS
20 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 IDP-126 for Acne (April 22, 2021)
27 VB 1953 for Acne (June 16, 2020)
29 DMT310 for Acne (June 10, 2020)
31 FCD105 for Acne (June 2, 2020)
34 KEY UPCOMING EVENTS
35 KEY REGULATORY EVENTS
35 Upsher-Smith Adds Absorica Alternatives
35 Sol-Gel Celebrates Twyneo Approval
35 Teva Launches First Generic Of Sun’s Absorica In US
36 PROBABILITY OF SUCCESS
37 LICENSING AND ASSET ACQUISITION DEALS
37 Upsher-Smith Enters Into An Agreement With Mayne Pharma
37 Sun Strikes Deal For Clascoterone In US And Canada
37 Unilever Goes To Multi-Omics Data With Goal Of Personalizing Acne Intervention
37 GSK Inks Dermatology Pact With Eligo
38 L’Oreal’s Microbiome Explorations Lead To Micreos Deal For Next-Gen Antibacterial
39 REVENUE OPPORTUNITY
41 CLINICAL TRIAL LANDSCAPE
42 Sponsors by status
43 Sponsors by phase
44 Recent events
45 BIBLIOGRAPHY
46 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of acne, 2019–28
20 Figure 2: Overview of pipeline drugs for acne in the US
20 Figure 3: Pipeline drugs for acne, by company
21 Figure 4: Pipeline drugs for acne, by drug type
21 Figure 5: Pipeline drugs for acne, by classification
27 Figure 6: IDP-126 for Acne (April 22, 2021): Phase III – Study 302
29 Figure 7: VB 1953 for Acne (June 16, 2020): Phase II – Facial Acne Vulgaris
31 Figure 8: DMT310 for Acne (June 10, 2020): Phase IIb – 003
33 Figure 9: FCD105 for Acne (June 2, 2020): Phase II – Acne Vulgaris
34 Figure 10: Key upcoming events in acne
36 Figure 11: Probability of success in the dermatology-general pipeline
41 Figure 12: Clinical trials in acne
41 Figure 13: Top 10 drugs for clinical trials in acne
42 Figure 14: Top 10 companies for clinical trials in acne
42 Figure 15: Trial locations in acne
43 Figure 16: Acne trials status
44 Figure 17: Acne trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of acne, 2019–28
15 Table 2: Marketed drugs for acne
22 Table 3: Pipeline drugs for acne in the US
26 Table 4: IDP-126 for Acne (April 22, 2021)
27 Table 5: VB 1953 for Acne (June 16, 2020)
30 Table 6: DMT310 for Acne (June 10, 2020)
32 Table 7: FCD105 for Acne (June 2, 2020)
39 Table 8: Historical global sales, by drug ($m), 2016–20
40 Table 9: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Renal Cell Carcinoma (RCC) 
Sign up to the